Showing results (11-20 of 25) with videos related to
Sort By:
Pageof 3
Diabetes & Metabolic Syndrome|November 30, 2025
Low dose pioglitazone (7.5 mg) provides efficacious glycemic control in Asian Indian patients with poorly controlled diabetes compared to 15 mg: A pilot randomized controlled parallel-group open-label trial over 12 monthsRohit Barnabas, Shruti Bhide, Saba Samad Memon, et al.Expert Review of Molecular Diagnostics|March 6, 2018
The clinical significance of B-cell maturation antigen as a therapeutic target and biomarkerEric Sanchez, Edward J Tanenbaum, Saurabh Patil, et al.Journal of Pharmaceutical and Biomedical Analysis|May 21, 2019
Diablo ubiquitination analysis by sandwich immunoassayArcan Guven, Wenfang S Wu, Saurabh Patil, et al.Journal of Immunological Methods|October 5, 2017
Human CCDC47 sandwich immunoassay development with electrochemiluminescence technologyWenfang S Wu, Liang Zhu, Saurabh Patil, et al.Annals of Hematology|January 13, 2019
The anti-myeloma effects of the selective JAK1 inhibitor (INCB052793) alone and in combination in vitro and in vivoEric Sanchez, Mingjie Li, Saurabh Patil, et al.British Journal of Haematology|April 23, 2020
Estimating a normal reference range for serum B-cell maturation antigen levels for multiple myeloma patientsScott Jew, Sean Bujarski, Camilia Soof, et al.Molecular Therapy. Nucleic Acids|May 20, 2022
Preclinical evaluation of WVE-004, aninvestigational stereopure oligonucleotide forthe treatment of <i>C9orf72</i>-associated ALS or FTDYuanjing Liu, Amy Andreucci, Naoki Iwamoto, et al.British Journal of Haematology|May 23, 2020
Normalization of serum B-cell maturation antigen levels predicts overall survival among multiple myeloma patients starting treatmentScott Jew, Tiffany Chang, Sean Bujarski, et al.Targeted Oncology|December 13, 2017
The Role of B-Cell Maturation Antigen in the Biology and Management of, and as a Potential Therapeutic Target in, Multiple MyelomaEric Sanchez, Emily J Smith, Moryel A Yashar, et al.Targeted Oncology|June 7, 2021
Baseline and Changes in Serum B-Cell Maturation Antigen Levels Rapidly Indicate Changes in Clinical Status Among Patients with Relapsed/Refractory Multiple Myeloma Starting New TherapySean Bujarski, Kyle Udd, Camilia Soof, et al.Pageof 3